Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
31 Octobre 2023 - 9:15PM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing novel targeted therapies for
RAS-addicted cancers, today announced that it will report financial
results for the third quarter 2023 on Monday, November 6, 2023,
after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m.
Pacific Time), Revolution Medicines’ senior management team will
host a webcast to discuss the financial results for the quarter and
provide an update on corporate progress.
To listen to the live webcast, or access the
archived webcast, please visit:
https://ir.revmed.com/events-and-presentations. Following the live
webcast, a replay will be available on the company’s website for at
least 14 days.
About Revolution Medicines,
Inc.Revolution Medicines is a clinical-stage oncology
company developing novel targeted therapies for RAS-addicted
cancers. The company’s R&D pipeline comprises RAS(ON)
Inhibitors designed to suppress diverse oncogenic variants of RAS
proteins, and RAS Companion Inhibitors for use in combination
treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236
(RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are
currently in clinical development. Additional RAS(ON) Inhibitors in
the company’s pipeline include RMC-5127 (KRASG12V), RMC-0708
(KRASQ61H) and RMC-8839 (KRASG13C) which are currently in
IND-enabling development, and additional compounds targeting other
RAS variants.
Investors & Media Contact:
Erin Graves
650-779-0136
egraves@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Revolution Medicines (NASDAQ:RVMD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024